Detalhe da pesquisa
1.
Cross-Reactivity of Antibodies to Rituximab with Other Therapeutic Anti-CD20 Antibodies.
J Immunol
; 212(4): 529-533, 2024 Feb 15.
Artigo
Inglês
| MEDLINE | ID: mdl-38149924
2.
Clinical and humoral responses after SARS-CoV-2 breakthrough infections in patients with immunosuppressants.
J Allergy Clin Immunol
; 2024 May 17.
Artigo
Inglês
| MEDLINE | ID: mdl-38763170
3.
Ocrelizumab Concentration Is a Good Predictor of SARS-CoV-2 Vaccination Response in Patients with Multiple Sclerosis.
Ann Neurol
; 93(1): 103-108, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36250739
4.
Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after mRNA vaccination.
Allergy
; 2024 Mar 04.
Artigo
Inglês
| MEDLINE | ID: mdl-38439527
5.
T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination.
J Neurol Neurosurg Psychiatry
; 2024 Mar 28.
Artigo
Inglês
| MEDLINE | ID: mdl-38548324
6.
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).
J Neurol Neurosurg Psychiatry
; 95(5): 392-400, 2024 Apr 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37963723
7.
Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis.
Mult Scler
; 30(2): 266-271, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-38235514
8.
Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod.
Mult Scler
; 30(3): 443-447, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-37942812
9.
Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis.
J Neuroinflammation
; 20(1): 215, 2023 Sep 26.
Artigo
Inglês
| MEDLINE | ID: mdl-37752582
10.
Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations.
J Autoimmun
; 135: 102984, 2023 02.
Artigo
Inglês
| MEDLINE | ID: mdl-36621174
11.
Association of age and inflammatory disease activity in the pivotal natalizumab clinical trials in relapsing-remitting multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 94(10): 792-799, 2023 10.
Artigo
Inglês
| MEDLINE | ID: mdl-37173129
12.
Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 94(6): 482-486, 2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-36639226
13.
SARS-CoV-2 omicron breakthrough infections in patients with multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 94(4): 280-283, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36564175
14.
Ocrelizumab concentration and antidrug antibodies are associated with B-cell count in multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 94(6): 487-493, 2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-36693720
15.
Fingerprick blood samples to measure serum natalizumab concentrations.
Mult Scler
; 29(3): 457-460, 2023 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-36448735
16.
Personalized monitoring of ambulatory function with a smartphone 2-minute walk test in multiple sclerosis.
Mult Scler
; 29(4-5): 606-614, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36755463
17.
Sensorimotor network dynamics predict decline in upper and lower limb function in people with multiple sclerosis.
Mult Scler
; 29(1): 81-91, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36177896
18.
Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light.
Mult Scler
; 29(10): 1229-1239, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37530045
19.
Association between age and inflammatory disease activity on magnetic resonance imaging in relapse onset multiple sclerosis during long-term follow-up.
Eur J Neurol
; 30(8): 2385-2392, 2023 08.
Artigo
Inglês
| MEDLINE | ID: mdl-37170817
20.
Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity.
BMC Infect Dis
; 23(1): 332, 2023 May 17.
Artigo
Inglês
| MEDLINE | ID: mdl-37198536